SEC Form 4 · accession 0000899243-16-012336
Aegerion Pharmaceuticals, Inc. · AEGR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sandford D Smith
Director
Period of report
Jan 27, 2016
Accepted (ET)
Jan 29, 2016 · 6:05 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001338042
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 27, 2016 | M | 2,223 | — | A | 2,223 | D | |
| Common Stock | Jan 27, 2016 | F | 778 | $6.78 | D | 1,445 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Jan 27, 2016 | M | 2,223 | D | — | — | Common Stock | 2,223 | 11,110 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock.
- F216.67% of the grant vested on January 27, 2016. Subject to the Reporting Person continuing to serve as a member of the board of Aegerion Pharmaceuticals, Inc., an additional 16.67% of the grant will vest on each of July 27, 2016; January 27, 2017; July 27, 2017; January 27, 2018; and August 21, 2018.